Early-stage and seed-stage funding for healthcare founders, with regulatory depth behind it.
We back healthcare founders from pre-seed through Series A, and join later rounds alongside co-investors. That includes medtech and diagnostics, drugs and biologics, hospitals and care delivery, and other healthcare businesses. Where a product is regulated, our regulatory read comes before capital moves, not after.
- First conversation
We learn the company, the stage, and what you are raising.
- First read
A short scientific, regulatory, and commercial read, to decide whether the company earns full diligence.
- Diligence
Full review across science, regulation, and the business, run alongside co-investors where they are in the round so the work is not duplicated.
- Decision and terms
Findings are written up plainly. Regulatory and scientific risk is reflected in valuation and, where appropriate, tied to milestones in the terms.
- Closing and support
Closing, then regulatory support from day one where the product is regulated, and follow-on decisions informed by real progress.
- Regulatory pathway assessed before capital is committed
Before any term sheet, we assess the likely FDA pathway, classification, and predicate landscape for the device. Founders get a straight answer on regulatory risk as part of diligence, not a surprise six months after the round closes.
- Regulatory support from day one, through every FDA milestone
Portfolio founders get direct access to regulatory guidance from the moment capital is deployed, not after a Series A when the product architecture is already locked in. Support continues through each submission, review cycle, and deficiency response.
- Co-investment without requiring exclusivity
We participate alongside angel groups, syndicates, and institutional investors, and bring regulatory diligence into the round for every investor at the table, not just ourselves.
- Series A and beyond, through co-investment
At later rounds, regulatory risk usually has the largest effect on valuation, and most generalist investors have the least ability to evaluate it. We invest within our usual range alongside VC and PE funds, adding regulatory-specific evaluation that complements their commercial and financial diligence.
- Follow-on informed by real submission progress
Because the same team that invests also evaluates regulatory milestones directly, follow-on decisions rest on a genuine read of submission progress, not just a founder update deck.
What size of investment can I expect?
Typically ₹25 lakh to ₹5 crore per investment, from our own family office. In larger rounds, we invest within that range alongside co-investors.
Which stages do you invest in?
Pre-seed through Series A, and later rounds alongside co-investors.
Do you require exclusivity?
No. We participate alongside angel groups, syndicates, and institutional investors, and bring our regulatory diligence to every investor in the round.
What kinds of companies do you back?
Healthcare founders across the sector: medtech and diagnostics, drugs and biologics, hospitals and care delivery, and other healthcare businesses.
Do you only back FDA-regulated companies?
No. Where a product is FDA-regulated, our regulatory read and support are a real advantage. Where it is not, we assess the team, the science, the market, and the economics in the same way.
Can I get regulatory help without taking your investment?
Yes. Tacticity Advisors, our regulatory consulting practice, works with device and pharmaceutical companies independently of any investment. See our services.